Scarica l'app Stockscreener
9.07
4.53%
-0.43
Dopo l'orario di chiusura:
9.25
0.18
+1.98%
Precedente Chiudi:
$9.50
Aprire:
$9.45
Volume 24 ore:
176.80K
Relative Volume:
0.52
Capitalizzazione di mercato:
$297.48M
Reddito:
$65.42M
Utile/perdita netta:
$-32.96M
Rapporto P/E:
-7.1417
EPS:
-1.27
Flusso di cassa netto:
$-19.87M
1 W Prestazione:
-0.11%
1M Prestazione:
-15.71%
6M Prestazione:
-38.24%
1 anno Prestazione:
+12.39%
Intervallo 1D:
$9.06
$9.45
Intervallo di 1 settimana:
$9.00
$9.61
Portata 52W:
$5.45
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Nome
Neuropace Inc
Settore
Industria
Telefono
(650) 237-2700
Indirizzo
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Confronta NPCE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
9.07 | 306.67M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
125.64 | 218.92B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.21 | 152.62B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
396.66 | 153.22B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
92.32 | 117.89B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
75.80 | 45.12B | 5.54B | 4.18B | 623.10M | 7.00 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-28 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-21 | Iniziato | UBS | Buy |
| 2024-03-14 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Iniziato | Leerink Partners | Outperform |
| 2023-11-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Iniziato | Lake Street | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Iniziato | Robert W. Baird | Outperform |
| 2021-05-17 | Iniziato | JP Morgan | Overweight |
| 2021-05-17 | Iniziato | Morgan Stanley | Overweight |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-17 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Neuropace Inc Borsa (NPCE) Ultime notizie
What analysts say about NeuroPace Inc. stockFastest return on investment - Autocar Professional
NeuroPace Inc. Stock Analysis and ForecastFree Bull & Bear Market Updates - jammulinksnews.com
Is NeuroPace Inc. a good long term investmentPhenomenal capital gains - Autocar Professional
What drives NeuroPace Inc. stock priceTriple-digit returns - jammulinksnews.com
NeuroPace, Inc. (NPCE) Backed by Cantor Fitzgerald Following Physician Survey - MSN
NeuroPace secures $75M credit facility with MidCap Financial - MSN
(NPCE) Proactive Strategies - news.stocktradersdaily.com
What makes NeuroPace Inc. stock price move sharplyFree Investing Community - Newser
How NeuroPace Inc. stock performs during market volatilityFree Stock Selection - Newser
Why NeuroPace Inc. stock attracts strong analyst attentionFree Stock Market Query - Newser
NeuroPace appoints Patrick Williams as CFO - MSN
NeuroPace’s SWOT analysis: innovative epilepsy treatment stock faces growth hurdles By Investing.com - Investing.com South Africa
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, ... - Bluefield Daily Telegraph
NeuroPace’s SWOT analysis: innovative epilepsy treatment stock faces growth hurdles - Investing.com
NeuroPaceVolatile, Uncertain, But Promising (NASDAQ:NPCE) - Seeking Alpha
NeuroPace Inc (NPCE) Trading Down 3.93% on Jun 27 - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc.NPCE - WV News
NeuroPace stock maintains outperform rating at Leerink on expansion outlook - Investing.com
NeuroPace stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com UK
NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm - WV News
NeuroPace's NAUTILUS Fallout: A Shareholder's Guide to Fraud Claims and Recovery - AInvest
Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load? - simplywall.st
Metric Analysis: NeuroPace Inc (NPCE)’s Key Ratios in the Limelight - DWinneX
10 Best NASDAQ Stocks Under $50 to Buy - Insider Monkey
Two Sigma Investments LP Invests $293,000 in NeuroPace, Inc. (NASDAQ:NPCE) - MarketBeat
Cantor Fitzgerald Comments on NeuroPace FY2026 Earnings - MarketBeat
Bank of America Corp DE Raises Position in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Shareholders to Connect - ACCESS Newswire
Neuropace Inc Azioni (NPCE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.03%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):